GHK-Cu for Hair Growth: Evidence, Off-Label Use, and Monitoring

Is any GHK-Cu product approved for hair growth?

No. FDA has not approved any drug containing GHK-Cu; it appears on FDA's compounding material as a nominated bulk drug substance, not as an approved medicine [1]. Copper histidinate (Zycubo) is a different compound, which FDA approved on January 12, 2026 for Menkes disease in children [10].

That makes the word off-label a poor fit. Off-label prescribing normally means using an approved drug outside its approved use. There is no approved GHK-Cu product to use that way. What people actually buy is either a cosmetic or a compounded preparation. Compounded drugs are not FDA-approved, meaning FDA does not review their safety, effectiveness or quality before they reach patients [11].

What the human hair data show

One human study gave a formulation containing copper tripeptide-1 to people with hair loss. Kapoor and colleagues ran an open-label, single-arm pilot in which 1,000 patients received intradermal scalp injections every three weeks for eight sessions [2]. The injected formulation contained vascular endothelial growth factor, basic fibroblast growth factor, insulin-like growth factor, keratinocyte growth factor, thymosin beta-4 and copper tripeptide-1, so no result can be credited to the copper peptide alone [2].

Hair pull testing showed reduced hair fall in 83% of patients. Videomicroscopy showed most patients had fewer vellus hairs, more terminal hairs and increased shaft diameter. Seventy-five percent of patients believed the injections were helping, and a significant increase in total hair count was still present at one year (P = 0.002). Treatment was reported as well tolerated [2].

With no control arm, the results cannot be separated from the other five growth factors in the mixture, from the injections themselves, or from the natural course of pattern hair loss.

What the laboratory work on copper peptides shows

The most directly relevant laboratory paper did not test GHK-Cu. It tested AHK-Cu, a different tripeptide-copper complex, on human hair follicles maintained ex vivo and on cultured dermal papilla cells [12]. Between 10^-12 and 10^-9 M, AHK-Cu stimulated follicle elongation and dermal papilla cell proliferation, and reduced the number of apoptotic dermal papilla cells, although that last change was not statistically significant [12]. This is tissue and cell work, not a clinical result.

For GHK-Cu itself, the actions usually quoted come from a narrative review by the researchers who proposed them. GHK is reported to stimulate collagen and proteoglycan production, modulate metalloproteinases, attract immune and endothelial cells to an injury, and accelerate wound healing in dogs, rats, mice and pigs; the same review states it can up- and downregulate at least 4,000 human genes [13]. These are proposed and preclinical mechanisms, not demonstrated effects on human hair [13].

The best-controlled topical trials were not in hair

Two randomized human trials of topical copper peptides were identified, and both tested skin rather than scalp [6][7]. In a trial in which 13 patients completed follow-up, a copper tripeptide product was applied after CO2 laser resurfacing around the mouth. Computer analysis and blinded evaluators found no significant difference in redness resolution, wrinkles or overall skin quality, while a patient questionnaire did favor GHK-Cu for overall skin quality (P = .04) [6]. In an 86-patient venous ulcer trial, a 0.4% tripeptide copper complex cream worked no better than an inert vehicle, while silver sulfadiazine 1% did reduce ulcer size [7].

A 2026 systematic review covering 2005 to 2026 concluded that, despite four decades of preclinical work, the human literature remains thin and fragmented: most randomized trials are small, run on facial cosmetic creams, and microneedle delivery of GHK-Cu has not been evaluated in a single registered, adequately powered human randomized trial [3].

Is a copper peptide hair serum a cosmetic or a drug?

FDA decides by intended use. Cosmetics other than color additives do not need FDA approval before they are sold, but a product intended to treat disease or to affect the structure or function of the body is a drug and must meet drug requirements [5]. FDA's own examples of claims that turn a product into a drug include claims that it will restore hair growth or regenerate cells [5]. A serum sold with such claims is therefore legally a drug, and since no GHK-Cu drug is approved, no such product has passed drug review [1][5].

Compounded and injectable GHK-Cu: where FDA stands

For state-licensed pharmacies and physicians, FDA lists GHK-Cu except for injectable routes of administration in category 1, the group under evaluation for the bulks list. FDA says it generally does not intend to act against compounders for category 1 substances when the conditions in its guidance are met [1][8]. The listing has moved: GHK-Cu came off category 1 on April 22, 2026 when the nominations were withdrawn, and was added back after a nominator clarified that only the injectable route had been withdrawn, with the list updated May 14, 2026 [1]. FDA has said it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 on whether to include GHK-Cu on the bulks list; no vote has taken place yet [1].

The injectable route is treated differently. FDA's page on bulk substances that may raise significant safety risks, content dated 04/22/2026, lists GHK-Cu for injectable routes in the nominated-but-withdrawn table, with the stated concern that compounded injectable drugs containing GHK-Cu may pose a risk for immunogenicity due to the potential for aggregation and peptide-related impurities, and that there are limited human data to inform safety considerations [4]. Injectable GHK-Cu is not in category 1 and is not in any category on FDA's current list [1]. It is also not one of the six peptides named in HHS's October 2026 draft enforcement-discretion policy [14].

What monitoring is actually supported

No FDA-approved GHK-Cu product exists, so there is no label-specified monitoring schedule for it [1]. The abstracts of the human trials described above do not describe serum copper checks [6][7][2]. In the injected-mixture pilot, hair pull tests were done before each session, and videomicroscopic and global images were taken at baseline, at sessions four and eight, and two months after the final session; the one-year total hair count was reported separately [2].

What to watch for

For injectables, FDA's concern is immunogenicity from aggregation and peptide-related impurities, alongside limited human safety data [4]. For topicals, the trial abstracts above do not report adverse-event rates. The injected mixture in the hair pilot was described as well tolerated [2].